Kevin Mohatt / The Washington Put up / Getty Photographs
Key Takeaways
- Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it launched knowledge from a brand new weight reduction drug trial.
- The brand new drug, CagriSema, led sufferers to lose 22.7% of their physique weight on common, beneath the corporate's reported purpose of 25%, per Bloomberg.
- The drug combines semaglutide, the lively ingredient in Ozempic and Wegovy, with one other ingredient meant to scale back starvation and make sufferers really feel full for longer.
Novo Nordisk’s (NVO) U.S.-listed shares sank over 19% in premarket buying and selling Friday after releasing trial outcomes for its subsequent era of weight reduction drug, meant so as to add to its present lineup of Ozempic and Wegovy.
The Danish drugmaker’s inventory was down 17% Friday morning after it had already been trending decrease since September, when gross sales slowed barely and considerations began to develop concerning the rising competitors within the weight reduction drug market.
New Drug Led to 22.7% Weight Loss
Novo Nordisk mentioned Friday that within the research of simply over 3,400 sufferers, its new injectable weight reduction drug CagriSema met its main purpose, with a median weight lack of 22.7% of a affected person's physique weight.
That in comparison with 11.8% and 16.1% of physique weight misplaced by the sufferers who took doses of simply one of many two medication that make up CagriSema, cagrilintide and semaglutide — the latter of which is the lively ingredient in Ozempic and Wegovy.
The elements within the drug are designed to imitate chemical compounds launched within the physique after individuals eat, serving to individuals really feel full for longer, making it simpler to scale back how a lot they eat.
The 22.7% common mark fell in need of Novo Nordisk's purpose reported final month by Bloomberg of 25% weight reduction. Novo Nordisk mentioned about 40% of individuals taking CagriSema reached the 25% mark.
Simply 57% of CagriSema sufferers reached the best dosage stage of the drug accessible in the course of the trial, in comparison with 82.5% and 70.2% of the cagrilintide and semaglutide sufferers, respectively, who took the best dose of these medication.
Novo Nordisk’s U.S. shares had been down 19.5% in premarket buying and selling, poised to open at their lowest level since August 2023, after getting into the day roughly flat this yr. Shares of weight reduction rival Eli Lilly (LLY) rose 7% following the trial outcomes.
Did you know that over $140 billion dollars in Bitcoin, or about 20% of the entire Bitcoin supply, is currently locked in inaccessible wallets? Or maybe you have lost access to your Bitcoin wallet? Don’t let those funds remain out of reach! AI Seed Phrase Finder is here to help you regain access effortlessly. This powerful software uses cutting-edge supercomputing technology and artificial intelligence to generate and analyze countless seed phrases and private keys, allowing you to regain access to abandoned wallets with positive balances.
